2013 Symposium Program

8:30 to 9 a.m.

9 to 9:10 a.m.
David Horne, Ph.D.
Interim Director, Beckman Research Institute
City of Hope
9:10 to 9:20 a.m.
Overview of Morning Session
John E. Shively, Ph.D.
City of Hope
9:20 to 10:10 a.m.
Early Recombinant Antibody Studies at City of Hope and Genentech
Arthur D. Riggs, Ph.D., City of Hope
Shmuel Cabilly, Ph.D., High Tech Investor and
Board Member Herbert Heynecker, Ph.D., Advisor, Thuja Capital
10:10 to 10:30 a.m.
10:30 to 11:20 a.m.
Engineered Antibodies for Molecular Imaging in Oncology and Beyond
Anna Wu, Ph.D., University of California
Los Angeles
11:20 a.m. to 12:10 p.m.
From Knobs-into-Holes to Onartuzumab
Paul Carter, Ph.D., Genentech
12:10 to 1:10 p.m.
1:10 to 1:20 p.m.
Overview of Afternoon Session
Andrew Raubitschek, M.D.
City of Hope
1:20 to 2:10 p.m.
Combinatorial and Evolutionary Engineering:
The Binders and Targets
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
2:10 to 3 p.m.
Targeting FcRn for Therapy
Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
3 to 3:20 p.m.
3:20 to 4:10 p.m.
Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D.
Seattle Genetics, Inc.
4:10 to 5 p.m.
Cancer Therapy by T Cell-engaging
Bispecific Antibodies
Patrick Baeuerle, Ph.D., Amgen Research,
Munich, Germany